Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence

Efficacy of atezolizumab plus bevacizumab for unresectable HCC: Systematic review and meta-analysis of real-world evidence

Background & Aims: Atezolizumab plus bevacizumab (A+B) is a standard-of-care treatment in unresectable hepatocellular carcinoma (uHCC). Verification of its effectiveness outside clinical trials is an area of unmet need, especially in estimating long-term survival outcomes. Methods: We conduc...

Full description

Saved in:
Bibliographic Details
Main Authors: Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, Bernardo Stefanini, Antonio D'Alessio, Matthias Pinter, Bernhard Scheiner, Nichola Awosika, Leonardo Brunetti, Pasquale Lombardi, Charles Latchford, Pei-Chang Lee, Yi-Hsiang Huang, Chun-Yen Lin, Andrea Dalbeni, Arndt Vogel, Peter R. Galle, Masatoshi Kudo, Lorenza Rimassa, Hong Jae Chon, Giuseppe Cabibbo, Fabio Piscaglia, Calogero Cammà, Anjana Pillai, Mario Pirisi, Amit G. Singal, David J. Pinato
Format: Article
Language:English
Published: Elsevier 2025-08-01
Series:JHEP Reports
Subjects:
HCC
Immunotherapy
RWE
Survival
Child–Pugh
Online Access:http://www.sciencedirect.com/science/article/pii/S2589555925001089
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items